Beyond a single biomarker
Analyze spatial and phenotypic patterns across the full visible tumor environment.
Oncology decision intelligence
See more inevery scan.
ONCOSENSE decodes tumor biology and host fitness from standard medical imaging—helping oncology teams reason about treatment benefit and safety before therapy begins.
Existing CT / MRIDICOM-readyClinician-in-the-loop
Decision intelligence
Whole-patient overview
Analysis ready
CT chest / abdomen
Automated phenotype map
Tumor region detected
Model confidence
High
82
Tumor biology
High signal
68
Host fitness
Moderate
Therapeutic index
Favorable profile
Predicted benefit is balanced against the individual safety signal.
Review with clinical team
Tumor phenotyping
Body composition
Toxicity risk
Response prediction
Clinical sensemaking
Tumor phenotyping
Body composition
Toxicity risk
Response prediction
Clinical sensemaking
The platform
From pixels to clinical meaning.
A scan contains more than anatomy. ONCOSENSE extracts complementary signals from the tumor and the person carrying it, then organizes those signals into a clear, reviewable clinical picture.
Signal 01
Tumor biology
Spatial heterogeneity, phenotype and microenvironment signals.
Signal 02
Host fitness
Muscle reserve, organ vulnerability and treatment tolerance.
Combined output
Clinical sensemaking
A balanced view of likely benefit, likely harm and the evidence behind both.
01
Existing imaging as input
02
Complementary biological signals
03
Explainable clinical outputs
04
Treatment pathways supported
Why it matters
Treatment is selected for a cancer. Toxicity happens to a person.
Precision oncology is incomplete when it only asks whether a tumor may respond. A clinically useful system must also ask whether the patient has the physiological reserve to tolerate the treatment.
ONCOSENSE brings efficacy and safety into the same conversation.
Beyond height and weight
Measure internal fitness using body composition and organ-level imaging signals.
Beyond a black-box score
Show the factors, confidence and uncertainty behind each decision-support output.
The four sensors
One operating system for the tumor board.
Modular intelligence for the four major treatment pathways—designed to grow into an automated multidisciplinary decision-support layer.
01
In development
Immuno-Sensor
Is the tumor biologically likely to respond?
Core technology
Radiomics + deep phenotype
02
Pilot pathway
Chemo-Sensor
Can this patient safely tolerate the dose?
Core technology
L3 body composition
03
Roadmap
Surgical-Sensor
What anatomy changes surgical feasibility?
Core technology
Vascular segmentation
04
Roadmap
Radio-Sensor
Which tissue is vulnerable to radiation injury?
Core technology
Parenchymal analysis
First clinical pathwayDiscuss a pilot
Chemo-Safety
Reveal hidden frailty before the first dose.
Body weight can hide major differences in muscle reserve and adipose distribution. ONCOSENSE automatically analyzes the L3 region from an existing CT to surface clinically relevant body-composition signals.
Automated L3 localization
Skeletal muscle and adipose segmentation
Muscle index and density calculation
Transparent risk stratification for clinical review
Chemo-Safety
L3 body composition analysis
Muscle
142 cm²
Visceral fat
88 cm²
L3 reference
Detected
Skeletal muscle index
41.8
cm²/m²
Frailty signal
Elevated
How it works
Intelligence that fits the clinical workflow.
Designed around the systems and review processes oncology teams already use—not as another disconnected dashboard.
STEP 01
Connect
Receive standard DICOM studies from PACS or a secure upload workflow.
STEP 02
Decode
Automatically localize anatomy, segment relevant regions and calculate imaging phenotypes.
STEP 03
Synthesize
Combine efficacy, safety and clinical context into a transparent decision-support signal.
STEP 04
Review
Present the evidence to the multidisciplinary team for informed clinical review.
Built for integration, not disruption.
DICOM-first architecture with pathways for PACS, clinical data and secure deployment.
DICOMPACSFHIR-readyOn-premise option
Our vision
Precision oncology accessible to every patient, everywhere.
A future where every treatment decision is informed by deeper biological insight—and where survival and quality of life are considered together.
Our mission
Make complex oncology data understandable and clinically useful.
We translate hidden imaging phenotypes into transparent, action-oriented evidence that supports—not replaces—the oncology team.
Build the next standard of care
Bring more sense to every oncology decision.
We are speaking with oncology centers, clinical researchers and technology partners interested in validation and pilot collaboration.